Savara (NASDAQ:SVRA) Issues Quarterly Earnings Results, Meets Expectations

Savara (NASDAQ:SVRA) announced its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11), Zacks reports.

Savara Trading Down 9.4 %

Shares of Savara stock traded down $0.36 during trading on Wednesday, reaching $3.47. The company’s stock had a trading volume of 2,077,425 shares, compared to its average volume of 1,206,000. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a 52-week low of $3.28 and a 52-week high of $5.70. The firm’s 50-day moving average is $3.96 and its two-hundred day moving average is $4.22. The company has a market cap of $571.16 million, a price-to-earnings ratio of -8.24 and a beta of 1.02.

Analysts Set New Price Targets

Several equities analysts have commented on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday. Finally, HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.